BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Chronic kidney disease clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for chronic kidney disease: 193 (117 sponsors; 37 newly posted in the last 180 days, 12 stopped in the last 180 days; 15 new-entrant sponsors). Momentum score 18.1, rank 33 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 2, Phase 1 25, Phase 2 30, Phase 3 44, Phase 4 8, N/A 84.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
AstraZeneca AZN15P3 6, NA 4, P4 1, P2 3, P1 134
Novartis Pharmaceuticals NVS6P3 5, P1 100
Eli Lilly and Company LLY4P3 3, P2 111
Bayer8NA 6, P3 212
Boehringer Ingelheim4P3 2, NA 204
Shandong Suncadia Medicine Co., Ltd.3P3 2, P1 110
Amgen AMGN2P3 200
Kind Pharmaceuticals LLC2P3 202
Novo Nordisk A/S NVO6NA 2, P1 1, P4 1, P2 1, P3 150
Eledon Pharmaceuticals ELDN3P2 2, P3 111
Prokidney PROK3P3 1, NA 200
Biohaven Therapeutics Ltd. BHVN2P3 1, P1 110
CSL Behring2P3 1, P1 110
Shaanxi Micot Pharmaceutical Technology Co., Ltd.2P3 1, P2 101
Alebund Pharmaceuticals1P3 100
Alexion Pharmaceuticals, Inc.1P3 100
AMAG Pharmaceuticals, Inc.1P3 100
Amicus Therapeutics1P3 101
Astellas Pharma Global Development, Inc.1P3 100
Biocad1P3 100
Dr. F. Köhler Chemie GmbH1P3 100
Ebima Clifford Okundaye1P3 100
Genexine, Inc.1P3 100
Humacyte, Inc. HUMA1P3 100
Iperboreal Pharma Srl1P3 101

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-26 est.P3Shaanxi Micot Pharmaceutical Technology Co., Ltd.NCT07122401 Study of MT1013 for the Treatment of Patients With Secondary HyperparathyroidismSecondary Hyperparathyroidism, Chronic Kidney Diseaserecruiting424
2026-12 est.P1/P2Ingenia Therapeutics INCNCT07231679 A Study to Investigate IGT-303 in Healthy Volunteers and Participants With Chronic Kidney DiseaseHealthy Volunteers; Chronic Kidney Diseaserecruiting94
2026-12-10 est.P2AstraZeneca AZNNCT07222917 A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic KiChronic Kidney Disease and Hypertensionactive not recruiting222
2026-12-31 est.P3Boehringer IngelheimNCT06531824 EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)Kidney Disease, Chronicactive not recruiting8371
2027-01 est.P1/P2AION Healthspan, Inc.NCT06721143 A Study to Investigate the Safety, Tolerability, and Preliminary Efficacy With AION-301 Administered by Intravenous Infusion Compared With Placebo Administered Chronic Kidney Disease Stage 3recruiting36

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10 est.P2/P3Ebima Clifford OkundayeNCT06866236 Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease ProgressionChronic Kidney Diseases; Acute Kidney Injury; Kidney Failurenot yet recruiting3000
2026-09-26 est.P2AstraZeneca AZNNCT06942910 A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease andChronic Kidney Disease With High Proteinuriaactive not recruiting224
2026-09-01 est.P2Novo Nordisk A/S NVONCT06717698 A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney DiseaseChronic Kidney Diseaserecruiting465
2026-09 est.P2Maze Therapeutics MAZENCT06830629 A Phase 2 Study of MZE829 in Adults With APOL1 Kidney DiseaseProteinuric Kidney Diseaserecruiting74
2026-08-31 est.P3AMAG Pharmaceuticals, Inc.NCT03619850 A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in PedChronic Kidney Disease; Iron Deficiency Anemiarecruiting129
2026-08-14P2Boehringer IngelheimNCT06926660 A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney DiseaseChronic Kidney Diseasecompleted492
2026-08-12P3Akebia Therapeutics AKBANCT06901505 To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center HemodialysisAnemia of Chronic Kidney Diseasecompleted353
2026-08-11 est.P2ZyVersa Therapeutics, Inc.NCT06489340 P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney DiseaseDiabetic Kidney Diseasewithdrawn
2026-07-20P2Vertex Pharmaceuticals Incorporated VERXNCT06794996 Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without ComorbiditiesProteinuric Kidney Diseasecompleted42
2026-07-06P2Eli Lilly and Company LLYNCT05536804 A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesOverweight; Obesity; Chronic Kidney Disease; Type 2 Diabetes; T2Dcompleted134
2026-07 est.P3Akebia Therapeutics AKBANCT05082584 Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-StimulatingAnemia of Chronic Kidney Diseasewithdrawn
2026-07 est.P3Akebia Therapeutics AKBANCT05082571 Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney DiseaseAnemia of Chronic Kidney Diseasewithdrawn
2026-06-20 est.P3Alebund PharmaceuticalsNCT06933472 A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and ChinaHyperphosphatemia; Chronic Kidney Disease, Receiving Dialysis; ESRD (End-Stage Renal Disease); Dialyrecruiting264
2026-06-09P3Novo Nordisk A/S NVONCT05021835 ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and InflammationCardiovascular Risk; Chronic Kidney Disease; Inflammationcompleted6385
2026-05-27P2Shenzhen Salubris Pharmaceuticals Co., Ltd.NCT07716618 A Phase II Clinical Trial of the Safety and Efficacy of SAL0120 in Patients With Chronic Kidney Disease (CKD)Chronic Kidney Diseaseactive not recruiting320

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "chronic kidney disease"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.